



28 March 2024

PHARMAC  
TE PĀTAKA WHAIORANGA

## Tender results

Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2023/24 Invitation to Tender, dated 31 October 2023.

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceutical under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.

### Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12<sup>th</sup> of April 2024 or the 5<sup>th</sup> of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12<sup>th</sup> of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://pharmac.govt.nz/medicine-funding-and-supply/make-an-application/pharmconnect-make-a-medicine-funding-application/process-for-notification-of-product-changes/>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/Pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5<sup>th</sup> of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.

## 2023/24 Tender – Principal Supply Status applies until 30 June 2027

### Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule

The decisions were as follows:

1. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date
Cinacalcet	Tab 30 mg; 28 tablet blister pack	\$42.06	\$25.24	Cinacalcet Devatis (Devatis)	1 July 2024	1 December 2024
Cinacalcet	Tab 60 mg; 28 tablet blister pack	\$84.12	\$50.47	Cinacalcet Devatis (Devatis)	1 July 2024	1 December 2024
Erlotinib	Tab 100 mg; 30 tablet blister pack	\$329.70	\$280.84	Alchemy (Alchemy)	1 May 2024	1 October 2024
Erlotinib	Tab 150 mg; 30 tablet blister pack	\$569.70	\$484.24	Alchemy (Alchemy)	1 May 2024	1 October 2024
Oxycodone hydrochloride	Inj 10 mg per ml, 1 ml ampoule; 5 ampoule pack	\$5.82	\$4.37	Hameln (Max Health)	1 July 2024	1 December 2024
Oxycodone hydrochloride	Inj 10 mg per ml, 2 ml ampoule; 5 ampoule pack	\$11.49	\$8.62	Hameln (Max Health)	1 July 2024	1 December 2024
Oxycodone hydrochloride	Inj 50 mg per ml ampoule; 5 ampoule pack	\$22.92	\$14.90	Hameln (Max Health)	1 July 2024	1 December 2024

2. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Listing date	Principal Supply date	Brand (Supplier) affected by delisting
Naloxone hydrochloride	Inj 400 mcg per ml, 1 ml ampoule; 5 ampoule pack	\$35.26	\$13.29	DBL Naloxone Hydrochloride (Pfizer)	1 November 2024	1 April 2025	Hamelin (Max Health)
Octreotide Long-Acting	Inj depot 30 mg prefilled syringe; 1 prefilled syringe pack	\$718.55	\$670.80	Sandostatin LAR (Novartis)	1 July 2024	1 December 2024	Octreotide Depot Teva (Teva)

3. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of Subsidy Change	Principal Supply date	Brand (Supplier) affected by delisting
Octreotide Long-Acting	Inj depot 10 mg prefilled syringe; 1 prefilled syringe pack	\$1,152.00	\$438.40	Sandostatin LAR (Novartis)	1 July 2024	1 December 2024	Octreotide Depot Teva (Teva)
Octreotide Long-Acting	Inj depot 20 mg prefilled syringe; 1 prefilled syringe pack	\$1,539.00	\$583.70	Sandostatin LAR (Novartis)	1 July 2024	1 December 2024	Octreotide Depot Teva (Teva)

**Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.**

4. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Date of subsidy change	Principal Supply date
Cinacalcet	Tab 30 mg; 28 tablet blister pack	\$42.06	\$25.24	Cinacalcet Devatis (Devatis)	5%	1 July 2024	1 December 2024
Cinacalcet	Tab 60 mg; 28 tablet blister pack	\$84.12	\$50.47	Cinacalcet Devatis (Devatis)	5%	1 July 2024	1 December 2024

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Date of subsidy change	Principal Supply date
Erlotinib	Tab 100 mg; 30 tablet blister pack	\$329.70	\$280.84	Alchemy (Alchemy)	5%	1 May 2024	1 October 2024
Erlotinib	Tab 150 mg; 30 tablet blister pack	\$569.70	\$484.24	Alchemy (Alchemy)	5%	1 May 2024	1 October 2024
Oxycodone hydrochloride	Inj 10 mg per ml, 1 ml ampoule; 5 ampoule pack	\$5.82	\$4.37	Hamelin (Max Health)	5%	1 July 2024	1 December 2024
Oxycodone hydrochloride	Inj 10 mg per ml, 2 ml ampoule; 5 ampoule pack	\$11.49	\$8.62	Hamelin (Max Health)	5%	1 July 2024	1 December 2024
Oxycodone hydrochloride	Inj 50 mg per ml ampoule; 5 ampoule pack	\$22.92	\$14.90	Hamelin (Max Health)	5%	1 July 2024	1 December 2024

5. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply date	Brand (Supplier) affected by delisting
Carboplatin <sup>1</sup>	Inj 10 mg per ml, 45 ml vial; 1 vial pack	\$45.20	\$25.73	Carboplatin Accord (Accord)	5%	1 July 2024	1 December 2024	Carboplatin Ebewe (Novartis)
Naloxone hydrochloride	Inj 400 mcg per ml, 1 ml ampoule; 5 ampoule pack	\$35.26	\$13.29	DBL Naloxone Hydrochloride (Pfizer)	5%	1 November 2024	1 April 2025	Hamelin (Max Health)
Octreotide	Inj depot 10 mg prefilled syringe; 1 prefilled syringe pack	\$439.97	\$438.40	Sandostatin LAR (Novartis)	5%	1 July 2024	1 December 2024	Octreotide Depot Teva (Teva)
Octreotide	Inj depot 20 mg prefilled syringe; 1 prefilled syringe	\$647.03	\$583.70	Sandostatin LAR (Novartis)	5%	1 July 2024	1 December 2024	Octreotide Depot Teva (Teva)

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply date	Brand (Supplier) affected by delisting
	pack							
Octreotide	Inj depot 30 mg prefilled syringe; 1 prefilled syringe pack	\$718.55	\$670.80	Sandostatin LAR (Novartis)	5%	1 July 2024	1 December 2024	Octreotide Depot Teva (Teva)
<sup>1</sup> The price and subsidy of carboplatin (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be listed at the above prices from 1 July 2024. The subsidy of carboplatin inj 1 mg for ECP (Baxter) will be reduced from \$0.10 per 1 mg to \$0.06 per 1 mg from 1 July 2024 in Section B of the Pharmaceutical Schedule.								

## Tender declines – Products where no tender is to be awarded for Principal Supply Status

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2023/24 Invitation to Tender, dated 31 October 2023.

Chemical Name	Line Item
Calcium folinate	Inj 1 g
Calcium folinate	Inj 100 mg
Calcium folinate	Inj 3 mg per ml, 1 ml
Calcium folinate	Inj 300 mg – 350 mg
Calcium folinate	Inj 50 mg
Calcium folinate	Tab 15 mg
Cinacalcet	Tab 90 mg
Hydrocortisone butyrate	Milky emulsion 0.1%
Hydrocortisone butyrate	Oint 0.1%
Hydrocortisone butyrate	Scalp lotn 0.1%
Lomustine	Cap 10 mg

Chemical Name	Line Item
Lomustine	Cap 40 mg
Octreotide (widened access)	Inj depot 10 mg prefilled syringe
Octreotide (widened access)	Inj depot 20 mg prefilled syringe
Octreotide (widened access)	Inj depot 30 mg prefilled syringe
Potassium citrate	Oral liq 3 mmol per ml
Salbutamol	Nebuliser soln, 1 mg per ml, 2.5 ml
Salbutamol	Nebuliser soln, 2 mg per ml, 2.5 ml
Salbutamol with ipratropium bromide	Nebuliser soln, 2.5 mg 5 mg with ipratropium bromide 0.5 mg per 2.5 ml
Vinorelbine	Inj 10 mg per ml, 1 ml
Vinorelbine	Inj 10 mg per ml, 5 ml

For products included in the 2021/22, 2022/2023 and 2023/24 Invitation to Tender where no announcement has yet been made, either a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.